Monopar Therapeutics
Monopar Therapeutics (MNPR): 6 pipeline candidates · ~97 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
96.8 months
D/E 0.02 · 0% dilution
Lead: Phase 3
6 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Monopar Therapeuticsacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$415.7M
Cash
$52.5M
Quarterly Burn
$3.5M
Runway
96.8 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| alxn1840 | Phase 3 |
| mnpr-101-ac | Preclinical |
| mnpr-101-dfo*-89zr | Phase 1 |
| mnpr-101-lu | Phase 1 |
| mnpr-101-pcta-177lu | Phase 1 |
| mnpr-101-zr | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$397.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,634,820 | $144.1M |
| ra capital management, l.p. | 667,207 | $36.6M |
| vanguard capital management llc | 436,926 | $23.9M |
| deerfield management company, l.p. | 323,745 | $17.7M |
| blackrock, inc. | 316,567 | $17.3M |
| adage capital partners gp, l.l.c. | 309,195 | $16.9M |
| adar1 capital management, llc | 264,278 | $14.5M |
| polar capital holdings plc | 226,526 | $12.4M |
| vivo capital, llc | 181,000 | $9.9M |
| wellington management group llp | 174,342 | $9.6M |
Showing top 10 of 79 institutional holders of Monopar Therapeutics. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Monopar Therapeutics's pipeline?
Monopar Therapeutics (MNPR) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Monopar Therapeutics's lead drug candidate?
Monopar Therapeutics's most advanced tracked candidate is alxn1840 (Phase 3) for Wilson disease.
What is Monopar Therapeutics's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Monopar Therapeutics has approximately 96.8 months of cash runway.
What is Monopar Therapeutics's market capitalization?
Monopar Therapeutics's market capitalization is approximately $415.7M.
Who is the CEO of Monopar Therapeutics?
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. is the chief executive officer of Monopar Therapeutics (MNPR).
Get the full picture on Monopar Therapeutics
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.